Gooreind Pharma
Gooreind Pharma has been active since 2004 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €390k and a net result of €59k. Equity is shrinking by ~8.2% per year across the filed fiscal years. Its solvency ranks better than 77% of 480 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.5% (low).
| Equity | €390k |
| Net result | €59k |
| Staff (FTE) | 4.4 |
| Better than sector | 77% |
Exceptional profile, strong across almost every axis.
All 5 axes are computed from data Checked has read.
How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 49.3% | 21.2% | |
| Net result | €59k | €32k | |
| Equity | €390k | €163k | |
| Gross operating margin | €487k | €281k | |
| Staff costs | €341k | €211k |
Figures by fiscal year and ratios
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Deposit | abbreviated schema | abbreviated schema | abbreviated schema | abbreviated schema |
| Revenue | - | - | - | - |
| EBITDA | €145k | €145k | €105k | €47k |
| Net profit | €59k | €57k | €35k | €19k |
| Cash flow | €114k | €114k | €93k | €74k |
| Staff costs | €341k | €315k | €328k | €212k |
| Income taxes | €23k | €22k | €136 | €609 |
| Dividends | €60k | €100k | €75k | - |
| Total assets | €791k | €880k | €924k | €921k |
| Equity | €390k | €391k | €434k | €474k |
| Debt | €401k | €489k | €491k | €448k |
| of which ≤ 1y | €216k | €264k | €226k | €140k |
| of which > 1y | €185k | €225k | €265k | €304k |
| Working capital | €295k | €288k | €320k | €356k |
| Employees (FTE) | 4.4 | 4.6 | 4.3 | 3.3 |
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Current ratio | 2.37 | 2.09 | 2.42 | 3.54 |
| Quick ratio | 1.33 | 1.28 | 1.41 | 2.15 |
| Working capital ratio | 37.3% | 32.7% | 34.6% | 38.7% |
| Solvency | 49.3% | 44.4% | 46.9% | 51.4% |
| Debt / equity | 1.03 | 1.25 | 1.13 | 0.95 |
| Long-term debt ratio | 0.48 | 0.58 | 0.61 | 0.64 |
| Interest coverage | 17.04 | 17.24 | 9.40 | 8.24 |
| Gross margin | - | - | - | - |
| Net margin | - | - | - | - |
| ROA | 7.5% | 6.5% | 3.8% | 2.1% |
| ROE | 15.2% | 14.6% | 8.1% | 4.0% |
| EBITDA margin | - | - | - | - |
| Days sales outstanding | - | - | - | - |
| Days payable outstanding | - | - | - | - |
| Inventory turnover | - | - | - | - |
| Days inventory (DSI) | - | - | - | - |
Full annual accounts (26 line items)
| Line item | Code | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Balance sheet, Assets | |||||
| TOTAL ASSETS | 20/58 | €791k | €880k | €924k | €921k |
| Fixed assets | 21/28 | €280k | €328k | €379k | €425k |
| Intangible fixed assets | 21 | €3k | €3k | - | - |
| Tangible fixed assets | 22/27 | €273k | €320k | €374k | €420k |
| Financial fixed assets | 28 | €5k | €5k | €5k | €5k |
| Current assets | 29/58 | €511k | €551k | €545k | €496k |
| Stocks & contracts in progress | 3 | €224k | €215k | €226k | €195k |
| Amounts receivable within one year | 40/41 | €164k | €232k | €161k | €186k |
| Cash & bank | 54/58 | €100k | €81k | €143k | €106k |
| Balance sheet, Equity & liabilities | |||||
| TOTAL EQUITY & LIABILITIES | 10/49 | €791k | €880k | €924k | €921k |
| Equity | 10/15 | €390k | €391k | €434k | €474k |
| Contributions / capital | 10/11 | €19k | €19k | €19k | €19k |
| Reserves | 13 | €371k | €371k | €414k | €412k |
| Accumulated profits (losses) | 14 | €0 | €0 | €0 | €42k |
| Amounts payable | 17/49 | €401k | €489k | €491k | €448k |
| Amounts payable after one year | 17 | €185k | €225k | €265k | €304k |
| Amounts payable within one year | 42/48 | €216k | €264k | €226k | €140k |
| Trade debts payable within one year | 44 | €73k | €79k | €59k | €72k |
| Income statement | |||||
| Gross operating margin | 9900 | €487k | €461k | €433k | €260k |
| Operating result | 9901 | €91k | €88k | €46k | €-7k |
| Financial income | 75 | - | - | €0 | €33k |
| Financial charges | 65 | €9k | €8k | €11k | €6k |
| Result before taxes | 9903 | €82k | €79k | €35k | €20k |
| Income taxes | 67/77 | €23k | €22k | €136 | €609 |
| Net result for the period | 9904 | €59k | €57k | €35k | €19k |
| Result to be appropriated | 9905 | €59k | €57k | €35k | €19k |
| NACE primary | Retail sale of pharmaceutical products(47730) |
| Legal form | Private limited company(610) |
| Incorporation | 06-12-2004 |
| Status | Active |
| Postal code | 2990 |
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 11682G0448/00W016 | Flanders | 1,269 m² | 1 · 470 m² | 12.6 m · 2 fl. |
We know of 3 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
23-11-2023 2 resigning
- Apotheek Dolhain, Bestuurder
- Kempen Pharma, Bestuurder
Technical details
{
"events": [
{
"kind": "rep_rotation",
"role": "vaste_vertegenwoordiger",
"person": {
"rrn": null,
"name": "SLEEUBUS Inge",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": "successor_conditional",
"via_org": {
"kbo": null,
"name": "Apotheek Dolhain",
"address": null,
"country": null,
"legal_form": "BV"
},
"statutory": null,
"compensated": null,
"effective_date": "2023-11-16",
"evidence_quote": "de beslissing van het bestuursorgaan van de bestuurder rechtspersoon, de BV \u201CApotheek Dolhain\u201D, om met ingang van 16-11-2023 als haar vaste vertegenwoordiger aan te duiden (in vervanging van de heer DOLHAIN Kristof): mevrouw SLEEUBUS Inge.",
"decharge_status": null,
"mandate_duration": {
"kind": "indefinite",
"value": null
},
"rep_rotation_new_rep": "SLEEUBUS Inge",
"rep_rotation_old_rep": "DOLHAIN Kristof",
"effective_date_qualifier": "immediate"
},
{
"kind": "rep_rotation",
"role": "vaste_vertegenwoordiger",
"person": {
"rrn": null,
"name": "KEMPEN Ineke",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": "confirmation",
"via_org": {
"kbo": null,
"name": "Kempen Pharma",
"address": null,
"country": null,
"legal_form": "BV"
},
"statutory": null,
"compensated": null,
"effective_date": null,
"evidence_quote": "het feit dat de bestuurder, BV \u201CKempen Pharma\u201D onveranderd als vaste vertegenwoordiger heeft: mevrouw KEMPEN Ineke.",
"decharge_status": null,
"mandate_duration": {
"kind": "indefinite",
"value": null
},
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
},
{
"kind": "mandate_termination_de_plein_droit",
"role": "bestuurder",
"person": null,
"reason": "de_plein_droit_dissolution",
"subkind": null,
"via_org": {
"kbo": null,
"name": "Apotheek Dolhain",
"address": null,
"country": null,
"legal_form": "BV"
},
"statutory": null,
"compensated": null,
"effective_date": null,
"evidence_quote": "kennisneming van 1. de beslissing van het bestuursorgaan van de bestuurder rechtspersoon, de BV \u201CApotheek Dolhain\u201D, om met ingang van 16-11-2023 als haar vaste vertegenwoordiger aan te duiden",
"decharge_status": null,
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
},
{
"kind": "mandate_termination_de_plein_droit",
"role": "bestuurder",
"person": null,
"reason": "de_plein_droit_dissolution",
"subkind": null,
"via_org": {
"kbo": null,
"name": "Kempen Pharma",
"address": null,
"country": null,
"legal_form": "BV"
},
"statutory": null,
"compensated": null,
"effective_date": null,
"evidence_quote": "kennisneming van 1. de beslissing van het bestuursorgaan van de bestuurder rechtspersoon, de BV \u201CApotheek Dolhain\u201D",
"decharge_status": null,
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
}
],
"notary": {
"name": "Yves De Deken",
"firm_city": null,
"firm_name": null,
"office_city": "Antwerpen",
"is_associated": false
},
"act_meta": {
"language": "nl",
"pub_date": "2023-11-23",
"filing_date": "2023-11-21",
"act_kind_objet": "Onderwerp akte:"
},
"decisions": [
{
"body": "buitengewone_algemene_vergadering",
"date": "2023-11-16",
"unanimous": null
}
],
"is_correction": false,
"subject_company": {
"kbo": "0870.403.170",
"name_full": "Apotheek Jacques",
"legal_form": "BV"
},
"publication_proxy": {
"kind": "org",
"org_kbo": "0662.975.105",
"org_name": "Van den Bempt-Michel \u0026 Partners",
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"uitgifte akte",
"statuten"
],
"corrected_publication_numac": null
}| Legal nameNL | Gooreind Pharma |